Pascal Touchon - 16 Aug 2022 Form 4 Insider Report for Atara Biotherapeutics, Inc. (ATRA)

Reporting relationship: President and CEO, Director
Issuer ticker: ATRA
Reported as of: 16 Aug 2022
Net transaction value: -$74,548
SEC form: 4
Accepted by SEC: 18 Aug 2022, 18:24:27 UTC
Prior SEC filing: 29 Jun 2022
Next SEC filing: 18 Nov 2022
Source filing: View source filing
Reporting owner signature: /s/ David Tucker, Attorney-in-Fact for Pascal Touchon

Key filing fact

Pascal Touchon filed Form 4 for Atara Biotherapeutics, Inc. (ATRA) on 18 Aug 2022.

Key facts

This page summarizes Pascal Touchon's Form 4 filing for Atara Biotherapeutics, Inc. (ATRA).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 18 Aug 2022, 18:24.

Change

Previous filing in this sequence was filed on 29 Jun 2022.
Current net transaction value: -$74,548.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

ATRA transaction

Common Stock

Sale

Transaction value: $74,548
Shares: -14,806
Change %: -3.1%
Price: $5.04
Shares after: 457,287
Date: 16 Aug 2022
Ownership: Direct
Footnotes: F1, F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

Shares sold pursuant to a 10b5-1 arrangement to satisfy tax obligations in connection with the vesting of previously granted restricted stock units.

Footnote F2

The sale price of the reporting person's shares represents the weighted average price of all shares sold by a broker on August 16, 2022 on behalf of a group of employees of the Issuer to satisfy the payment of withholding tax liability of such employee.